twoXAR Announces Formation of Business Advisory Board

Nov. 27, 2017 13:15 UTC

Industry veterans Judy Lewent, Jonathan MacQuitty, and Howie Rosen bring to twoXAR nearly 90 years of combined R&D and commercial experience in the biopharmaceutical sector

PALO ALTO, Calif.--(BUSINESS WIRE)-- twoXAR, an artificial intelligence (AI)-driven biopharmaceutical company, today announced the formation of its Business Advisory Board and the appointment of Judy Lewent, Jonathan MacQuitty, and Howie Rosen. The Advisory Board’s role will be to provide ongoing counsel, along with strategic guidance in business development decision-making, as the company advances its collaborations with biopharmaceutical companies and candidates in its pipeline.

“Since our founding in 2014, advice from veteran life science executives has been invaluable as twoXAR has successfully translated computational results into therapeutic development programs that leading pharmaceutical and biotechnology companies value,” said Andrew A. Radin, co-founder and Chief Executive Officer of twoXAR. “We are honored to announce the appointment of Judy, Jonathan, and Howie to our new Business Advisory Board and look forward to working with them to form new corporate collaborations and expand our drug candidate pipeline."

Judy has extensive knowledge of the global pharmaceutical industry and corporate finance, having joined Merck & Company in 1980 and then served as Chief Financial Officer from 1990 to 2007. Judy previously served as a Non-Executive Director of Dell, Quaker Oats Company, and Motorola. Judy is a Non-Executive Director of GlaxoSmithKline, Thermo Fisher Scientific and Motorola Solutions. She is also a Trustee of the Rockefeller Family Trust and Chairperson of the Audit Committee of Rockefeller Financial Services, a life member of the Massachusetts Institute of Technology (MIT) Corporation and a member of the American Academy of Arts and Sciences. She has a BS in Economics from Goucher College, and earned her SM from the MIT Sloan School of Management.

Jonathan is currently a Venture Partner at Lightspeed Ventures focusing on life science and healthcare investments. Jonathan has spent over 30 years in life science companies and in the venture capital sector that finances them. He was formerly a partner at Abingworth, a trans-Atlantic life science venture capital firm, heading up the firm’s West Coast office. Most recently he was the founding CEO of Forty Seven, an immuno-oncology company based in Menlo Park, CA. Jonathan serves on the board of directors of several Lightspeed companies and is Chairman of Personalis, which uses human genomic analysis for cancer research and treatment. He has also served on the Board of the Biotechnology Industry Organization (BIO). Jonathan has an MA in Chemistry from Oxford University, a PhD in Chemistry from the University of Sussex, and an MBA from Stanford University Graduate School of Business.

Howie is an independent consultant and serves on the board of directors of AcelRx Pharmaceuticals, where he served as CEO from 2015-17, Entrega, Kala Pharmaceuticals, where he served as Chairman from 2014-15, and Hammerton. He previously served on the board of directors of Alcobra, Aldea, Cotherix, CNS Therapeutics, Pearl Therapeutics, where he served as CEO from 2010-11, and Pharsight. He is a lecturer in the Department of Chemical Engineering at Stanford University and at the Stanford Graduate School of Business. Formerly, he was Vice President, Commercial Strategy at Gilead Sciences. Prior to joining Gilead, he was President of ALZA Corporation, a member of the Johnson & Johnson family of companies. He is a Fellow of the American Institute for Medical and Biological Engineering and a member of the National Academy of Engineering. He has a BS in Chemical Engineering from Stanford University, an MS in Chemical Engineering from MIT and an MBA from the Stanford Graduate School of Business.

About twoXAR

twoXAR is an artificial intelligence-driven biopharmaceutical company. The company leverages its computational platform to identify promising drug candidates, de-risks the opportunities through preclinical studies, and progresses drug candidates to the clinic through industry partnerships. Based in Palo Alto, California, the twoXAR team includes experts in drug discovery and development, biomedical informatics, computational biology, data science and software development. For more information, please visit



for twoXAR
Colin Sanford, 415-946-1094


Source: twoXAR, Inc.

Back to news